Abstract
Background
Patent ductus arteriosus (PDA) is a common complication seen in preterm infants. Indomethacin is routinely used to treat PDA. Evidence suggests that the response of indomethacin is highly heritable. This study investigated the association between single-nucleotide polymorphisms (SNPs) in CYP2C9 and the closure of PDA in response to indomethacin.
Methods
Six SNPs in CYP2C9 were analyzed for association with indomethacin response. A case–control analysis was performed among neonates who responded to indomethacin (responders) and among those who required surgical ligation (non-responders). Independent transmission disequilibrium tests were performed among parent–child trios of responders and non-responders.
Results
The G allele of rs2153628 was associated with increased odds of response to indomethacin in the case–control analysis (odds ratios (OR): 1.918, 95% confidence interval (CI): 1.056, 3.483). Among indomethacin responders, the G allele of rs2153628 and the T allele of rs1799853 were overtransmitted from the parents to their child (OR: 2.667, 95% CI: 1.374, 5.177 and OR: 2.375, 95% CI: 1.040, 5.425, respectively), consistent with the case–control analysis.
Conclusion
We identified an association between two SNPs in CYP2C9, rs2153628 and rs1799853, and indomethacin response for the treatment of PDA. These findings suggest that response to indomethacin in the closure of PDA may be influenced by polymorphisms associated with altered indomethacin metabolism.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Dagle JM, Lepp NT, Cooper ME et al. Determination of genetic predisposition to patent ductus arteriosus in preterm infants. Pediatrics 2009;123:1116–23.
Hajj H, Dagle JM . Genetics of patent ductus arteriosus susceptibility and treatment. Semin Perinatol 2012;36:98–104.
How Is Patent Ductus Arteriosus Treated? National Heart, Lung, and Blood Institute, 2011. Available at https://www.nhlbi.nih.gov/health/health-topics/topics/pda/treatment.
Gersony WM, Peckham GJ, Ellison RC, Miettinen OS, Nadas AS . Effects of indomethacin in premature infants with patent ductus arteriosus: results of a national collaborative study. J Pediatr 1983;102:895–906.
Shaffer CL, Gal P, Ransom JL et al. Effect of age and birth weight on indomethacin pharmacodynamics in neonates treated for patent ductus arteriosus. Crit Care Med 2002;30:343–8.
Smyth JM, Collier PS, Darwish M et al. Intravenous indometacin in preterm infants with symptomatic patent ductus arteriosus. A population pharmacokinetic study. Br J Clin Pharmacol 2004;58:249–58.
Lavoie PM, Pham C, Jang KL . Heritability of bronchopulmonary dysplasia, defined according to the consensus statement of the national institutes of health. Pediatrics 2008;122:479–85.
Meyer UA, Zanger UM . Molecular mechanisms of genetic polymorphisms of drug metabolism. Annu Rev Pharmacol Toxicol 1997;37:269–96.
Van Booven D, Marsh S, McLeod H et al. Cytochrome P450 2C9-CYP2C9. Pharmacogenet Genomics 2010;20:277–81.
Zhou SF, Zhou ZW, Yang LP, Cai JP . Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem 2009;16:3480–675.
Ali ZK, Kim RJ, Ysla FM . CYP2C9 polymorphisms: considerations in NSAID therapy. Curr Opin Drug Discov Dev 2009;12:108–14.
Barrett JC, Fry B, Maller J, Daly MJ . Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005;21:263–5.
de Bakker PI, Yelensky R, Pe'er I, Gabriel SB, Daly MJ, Altshuler D . Efficiency and power in genetic association studies. Nat Genet 2005;37:1217–23.
Spielman RS, McGinnis RE, Ewens WJ . Transmission test for linkage disequilibrium: the insulin gene region and insulin-dependent diabetes mellitus (IDDM). Am J Hum Genet 1993;52:506–16.
Wadelius M, Chen LY, Eriksson N et al. Association of warfarin dose with genes involved in its action and metabolism. Hum Genet 2007;121:23–34.
King BP, Khan TI, Aithal GP, Kamali F, Daly AK . Upstream and coding region CYP2C9 polymorphisms: correlation with warfarin dose and metabolism. Pharmacogenetics 2004;14:813–22.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
STATEMENT OF FINANCIAL SUPPORT
This research was also supported, in part, by the National Institutes of Health (HL109199, HD057192, HD052953, HD065786). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Rights and permissions
About this article
Cite this article
Smith, C., Ryckman, K., Bahr, T. et al. Polymorphisms in CYP2C9 are associated with response to indomethacin among neonates with patent ductus arteriosus. Pediatr Res 82, 776–780 (2017). https://doi.org/10.1038/pr.2017.145
Received:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/pr.2017.145
This article is cited by
-
Effect of CYP2C9 Polymorphisms on the Pharmacokinetics of Indomethacin During Pregnancy
European Journal of Drug Metabolism and Pharmacokinetics (2019)
